Tag: pcsk9

1. In this genetic association study, among 209 537 participants, a protein-truncating variant (PTV) was identified in 0.4% of individuals, ...

1. There was no association detected between PCSK9 gene variants and alterations in cardiac morphology. 2. The odds of having ...

1. In this case report, two patients who developed statin-associated autoimmune myopathy had their cholesterol levels effectively managed with the ...

1. In this systematic review and meta-analysis, more intensive compared with less itensive LDL-C lowering was associated with a greater ...

1. In addition to significantly lowering levels of low density lipoprotein cholesterol (LDL-C), evolocumab reduced the composite risk of cardiovascular ...

1. When added to statin therapy, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor bococizumab significantly reduced the risk of ...

1. This multi-year, open-label extension of phase 2 trials examining the LDL-lowering efficacy of evolocumab (PCSK9-inhibitor) showed that evolocumab plus ...

1. Among patients with muscle-related statin intolerance, evolocumab reduced LDL-C levels significantly more than ezetimibe. 2. Evolocumab and ezetimibe had ...

1. From a systematic review, proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies significantly reduced LDL cholesterol levels and all-cause mortality ...